Panacea and Bharat Biotech in talks for Covaxin production
Bharat biotech looks at contract manufacturing to expand its capacity amidst
growing demand for Covid-19 jabs.
09 April, 2021 Mumbai;Panacea Biotec seems to be interested in producing
the Covaxin vaccine. As per sources, Panacea hopes to enter into an agreement with
Bharat Biotech to produce Covaxin at the company's unit in Delhi.
COVAXIN, India's indigenous COVID-19 vaccine developed by Bharat Biotech in
collaboration with the Indian Council of Medical Research (ICMR) - National
Institute of Virology (NIV).
The Hyderabad based company looks at contract manufacturing options to expand its
capacity amidst growing demand for Covid-19 jabs. Discussions are at early stage.
It also seems that the two companies want the government to provide funding to
increase production capacity. Panacea is said to be ready to produce covaxin in
two to three months if it receives funding from the government. Panacea has the
Biosafety Level 3 manufacturing unit which is needed to make the coronavirus